Breast Cancer
Conditions
Brief summary
Biomarkers of resistance to neoadjuvant chemotherapy in locally advanced breast cancer
Detailed description
Identification and evaluation of biomarkers of resistance to neoadjuvant chemotherapy and establishment of preclinical models of resistance in locally advanced breast cancer
Interventions
BIOLOGICALBlood sample
Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture. These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study).
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* proven invasive breast adenocarcinoma (cytology and / or biopsy). * locally advanced stage (tumor size greater than 2 cm). * neoadjuvant chemotherapy indication validated RCP * Patient eligible for neoadjuvant chemotherapy. * Performance Index according to WHO or less 1. * Patient aged 18 years and older. * Being affiliated to a social security scheme or an equivalent scheme of social protection * Obtaining signed informed consent, and that before any specific prequalification testing.
Exclusion criteria
* presence of metastatic disease at diagnosis. * Breast Cancer inflammatory. * rare histologic subtypes (non ductal lobular and not). * Other cancer (except basal cell skin carcinoma and cancer of the cervix in situ adequately treated and curative) treated in the previous 5 years. * Patient pregnant or nursing or of childbearing age without effective contraception. * Breast cancer in men. * legal incapacity or limited legal capacity. medical or psychological conditions allowing the subject to complete the study or to sign the consent (art. L.1121-6, L.1121-7, L.1211-8, L1211-9).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| predictive molecular abnormalities assessment | up to 5 years | Highlighting and study of predictive molecular abnormalities of resistance to neoadjuvant chemotherapy in locally advanced breast cancer |
Countries
France
Outcome results
None listed